Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (April 2020)
17 slides from Revive Therapeutics's investor presentation, April 2020
Slide 1: A Specialty Life Sciences Company
A Specialty Life Sciences Company Corporate Presentation April 2020 Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: mfrank@revivethera.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS § Specialty life sciences company focused on repurposing drugs for rare disorders and infectious diseases § Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (Phase 3) Bucillamine § Developing novel Psiliocybin and Cannabidiol therapeutics
Slide 4: Pharmaceutical Strategy
PHARMACEUTICAL STRATEGY Clinical development of Targeting Rare Disorders Novel Uses, Targeting FDA Designations: Psilocybin, Cannabidiol and Infectious Diseases Formulations, and Orphan, Fast track, and Bucillamine Delivery System Breakthrough therapy and Rare pediatric diseases
Slide 5: Patent Portfolio
PATENT PORTFOLIO Title USPTO No. Status Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 62/991,996 Provisional patent filed Use of Bucillamine in the Treatment of Gout US9662305 Issued on May 30, 2017 US 8642088 Issued on February 4, 2014 Drug Delivery System US 954542
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases, including COVID-19, and Rare Disorders Stage of Regulatory Product Indication Market Development Status Infectious Diseases Bucillamine Filing IND IND for Phase 3 TBD (COVID-19) Target FDA Psilocybin Undisclosed Pre-clinical Orphan Status + $500M Undisc
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORUNTIY § Focus on Bucillamine in the treatment of infectious diseases § Well-known safety profile and prescribed for arthritis in Japan and South Korea for over 30 years § Revive’s clinical history with Bucillamine § Obtained 2 FDA INDs with Bucillamine and FDA orphan drug sta
Slide 8: Psychedelic Opportunity
PSYCHEDELIC OPPORTUNITY § Acquired Psilocin Pharma Corp. § Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis § Worked with Xanthic Bio Pharma and Green Growth Brands § Developed water Soluble THC and CBD products (Beverages, effervescent tablets) § Novel Psilocybin formulati
Slide 9: Formulation & Delivery Technology
FORMULATION & DELIVERY TECHNOLOGY § Delivering naturally extracted and synthetic psilocybin and cannabinoids § PSILOCYBIN - Precise dosed formulations i.e. capsules, sublingual spray, gel caps, effervescent tablets and oral/transmucosal strips § Releases (rapid, controlled, sustained), improved bioa
Slide 10: Liver Disease Opportunity
LIVER DISEASE OPPORTUNITY § Focus on Autoimmune Hepatitis (AIH) § AIH - rare disease (~ 76k patients in US) causing liver inflammation • Drawbacks of current therapies (steroids): Severe side effects in 13%, relapse after drug withdrawal in 50%-86%* § Obtained FDA orphan drug status for CBD in the t
Slide 11: Strategic Partners
STRATEGIC PARTNERS Infectious Diseases Acquired March 2020 R&D partnership Supply and collaboration CRO Psychedelic pharma Psychedelic pharma of truffles License of cannabidiol for License of cannabinoid Research collaboration treatment of Autoimmune delivery technology for liver diseases Hepatitis
Slide 12: Value Driving Milestones in 2020
VALUE DRIVING MILESTONES IN 2020 Q2 Submit FDA IND for Phase 3 clinical study of Bucillamine in the treatment of COVID-19 Q2 Initiate Phase 3 clinical study of Bucillamine in the treatment of COVID-19 in the U.S. Q2 Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatiti
Slide 13: Peer Comparison (Market Caps)
Peer Comparison (Market Caps) $3 Billion $190 Million $70 $70 $60 Million Million $35 Million Million
Slide 14: Organization
ORGANIZATION Management Board of Directors § Michael Frank § Michael Frank Chairman and CEO Chairman and CEO § Carmelo Marrelli § William Jackson Chief Financial Officer Director § Joshua Herman Clinical Director § Dr. Kelly McKee, Jr., MD, MPH § Christian Scovenna Chief Scientific Officer, Consulta
Slide 15: Stock Information
STOCK INFORMATION Ticker RVV (CSE) Share Price CAD $0.185 (April 23, 2020) 52 week High/Low CAD $0.23 / $0.025 Capital Structure 189,408,777 common shares (267,075,486 fully-diluted) Market Cap CAD ~ $35,000,000
Slide 16: Appendix – Bucillamine Scientific Rationale for COVID-19
Appendix – Bucillamine Scientific Rationale for COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac
Slide 17: Appendix – Bucillamine Scientific Rationale for COVID-19 References
Appendix – Bucillamine Scientific Rationale for COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
Revive Therapeutics — Investor Presentation (April 2020) on 6ix